Table 1.
Reactivity of anti-SIVgag antibodies in different settings
| Ab (NIH cat) | AG3.0 (4121) |
55-2F12 (1610) |
KK59 (2320) |
KK64 (2321) |
183-H12-5C (3537) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Technique | W | E | I | W | E | I | W | E | I | W | E | I | W | E | I |
| SIVmac239 | +c | +c | +d (poor) | +c,d | +c | +d | + [62] | +c | + [62] | +c | + [63] | +c | |||
| SIVmne | +a | −a | + [64] | ||||||||||||
| SIVmac251 | +b | −b | −b | + [65] | |||||||||||
| HIV-1 | +b | + [66] | + [67] | + [68] | + [69] | ||||||||||
W, Western blotting; E, ELISA; I, IFA. The source of antigens: arecombinant vaccinia infected cells, brecombinant antigen (catalogue #1845, NIH AIDS Research & Reference Reagent Program), crecombinant antigen (see Section 2) and dKunjin SIVgag VLP-infected cells.